Lunai Bioworks Inc.
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
No earnings releases found
Lunai Bioworks has not filed an earnings release (Form 8-K, Item 2.02) that we could match to a fiscal quarter.
Press releases
Announcements Lunai Bioworks filed with the SEC
SACRAMENTO, Calif., June 17, 2026
Other events · EX-99.1 to Form 8-K
LUNAI BIOWORKS, INC. ANNOUNCES REVERSE STOCK SPLIT
Other events · EX-99.1 to Form 8-K
Lunai Bioworks, Inc. Announces Postponement of Special
Other events · EX-99.1 to Form 8-K
Lunai Bioworks Executes $20M Strategic Transaction at Fixed $1.50 Conversion,
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
“ Agreement ”) is entered into as of [ ], 2025 (the “ Effective Date ”), by and between Renovaro Inc.,
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
NEITHER THIS PROMISSORY NOTE NOR THE
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.2 to Form 8-K
(To be executed by the Holder in order to convert
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.3 to Form 8-K
Renovaro and BioSymetrics Announce Definitive Merger
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Renovaro to Acquire Predictive Oncology in All-Stock Transaction
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Renovaro, Inc. Announces $10 million
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Renovaro Inc. and Amsterdam UMC Cancer Center Poised to Advance Cancer
Other events · EX-99.1 to Form 8-K
to Acquire 100% Ownership of Cyclomics, Reinforcing Cutting-Edge Cancer Diagnostics Partnership
Other events · EX-99.1 to Form 8-K
Pioneer GEDi Cube and Biotech Innovator Renovaro Biosciences Combine Forces to Accelerate Personalized Medicine
Material agreement · Acquisition or disposition completed · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
UNAUDITED PRO FORMA CONDENSED COMBINED
Material agreement · Acquisition or disposition completed · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Renovaro Biosciences Announces Results of Special Meeting of
Shareholder vote results · Other events · EX-99.1 to Form 8-K
Message from Renovaro Bioscience, Inc.’s CEO, The Hon.
Other events · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Other events · EX-99.2 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Renovaro Biosciences Inc. issued a press release announcing the appointment of Avram Miller to the Board of Directors.
Material agreement · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Renovaro Biosciences Appoints Two Finance Industry
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
AI Company GEDiCube and Renovaro Biosciences
Other events · EX-99.1 to Form 8-K
Renovaro Biosciences and AI Health Company GEDi Cube Sign Definitive
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
71-75 Shelton Street, Covent Garden
Regulation FD disclosure · EX-99.1 to Form 8-K
ENOCHIAN BIOSCIENCES INC. ANNOUNCES ADJOURNMENT
Shareholder vote results · Other events · EX-99.1 to Form 8-K
Enochian BioSciences Announces that its Cancer Platform
Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K
Enochian BioSciences Announces a Scientific Presentation
Other events · EX-99.1 to Form 8-K
Full Compliance with NASDAQ Filing Requirements
Other events · EX-99.1 to Form 8-K
Enochian BioSciences Announces Receipt of Notice
Material agreement · Listing notice · Regulation FD disclosure · EX-99.1 to Form 8-K
Enochian BioSciences Announces Receipt of Notice
Listing notice · Regulation FD disclosure · EX-99.1 to Form 8-K
Enochian BioSciences Forges Ahead With Focused Approach,
Other events · EX-99.1 to Form 8-K
Enochian BioSciences Announces Receipt of Notice
Listing notice · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K
Enochian BioSciences Awarded U.S. Patent For Its
Other events · EX-99.2 to Form 8-K
I have spoken to some of you about the serious and disturbing news that
Other events · EX-99.1 to Form 8-K
Enochian BioSciences Inc. (NASDAQ: ENOB)
Other events · EX-99.1 to Form 8-K
Enochian BioSciences Announces Findings From A Rigorous
Other events · EX-99.1 to Form 8-K
I have spoken to some of you about the serious and disturbing news that
Other events · EX-99.1 to Form 8-K
I have spoken to some of you about the serious and disturbing news that
Other events · EX-99.1 to Form 8-K
Scientific Leaders Agree on Promise of Enochian
Other events · EX-99.1 to Form 8-K